Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study

Clinical trial NCT04517526 · UNKNOWN

Trial details

NCT number: NCT04517526
Sponsor: Shanghai Cancer Hospital, China
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT

Start date: 2020-11-01
Primary completion: 2022-11-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.